JP2020128426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020128426A5 JP2020128426A5 JP2020093126A JP2020093126A JP2020128426A5 JP 2020128426 A5 JP2020128426 A5 JP 2020128426A5 JP 2020093126 A JP2020093126 A JP 2020093126A JP 2020093126 A JP2020093126 A JP 2020093126A JP 2020128426 A5 JP2020128426 A5 JP 2020128426A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heteroaryl
- compound according
- cycloalkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 83
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 230000029936 alkylation Effects 0.000 claims 10
- 238000005804 alkylation reaction Methods 0.000 claims 10
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 150000001345 alkine derivatives Chemical class 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 0 C[C@](CC1)N(C(*)=O)c(cc2)c1c1c2[n](C(CCC2)CC2C(O)=O)c(C(*)O)n1 Chemical compound C[C@](CC1)N(C(*)=O)c(cc2)c1c1c2[n](C(CCC2)CC2C(O)=O)c(C(*)O)n1 0.000 description 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692593P | 2018-06-29 | 2018-06-29 | |
| US62/692,593 | 2018-06-29 | ||
| PCT/US2018/051214 WO2019055869A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| WOPCT/US2018/051214 | 2018-09-14 | ||
| WOPCT/US2018/051235 | 2018-09-14 | ||
| PCT/US2018/051235 WO2019055877A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| US201962819490P | 2019-03-15 | 2019-03-15 | |
| US62/819,490 | 2019-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019123100A Division JP6781806B2 (ja) | 2018-06-29 | 2019-07-01 | Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020209005A Division JP2021042255A (ja) | 2018-06-29 | 2020-12-17 | Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020128426A JP2020128426A (ja) | 2020-08-27 |
| JP2020128426A5 true JP2020128426A5 (OSRAM) | 2021-02-04 |
| JP7017801B2 JP7017801B2 (ja) | 2022-02-09 |
Family
ID=68987627
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019123100A Active JP6781806B2 (ja) | 2018-06-29 | 2019-07-01 | Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害 |
| JP2020093126A Active JP7017801B2 (ja) | 2018-06-29 | 2020-05-28 | Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害 |
| JP2020209005A Withdrawn JP2021042255A (ja) | 2018-06-29 | 2020-12-17 | Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害 |
| JP2025046918A Pending JP2025094157A (ja) | 2018-06-29 | 2025-03-21 | Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019123100A Active JP6781806B2 (ja) | 2018-06-29 | 2019-07-01 | Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020209005A Withdrawn JP2021042255A (ja) | 2018-06-29 | 2020-12-17 | Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害 |
| JP2025046918A Pending JP2025094157A (ja) | 2018-06-29 | 2025-03-21 | Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10870648B2 (OSRAM) |
| EP (1) | EP3998266A1 (OSRAM) |
| JP (4) | JP6781806B2 (OSRAM) |
| KR (2) | KR20250067962A (OSRAM) |
| CN (2) | CN116178369A (OSRAM) |
| AU (3) | AU2019295790B2 (OSRAM) |
| BR (1) | BR112020026783A2 (OSRAM) |
| CA (1) | CA3105099A1 (OSRAM) |
| CY (1) | CY1124762T1 (OSRAM) |
| DK (1) | DK3587418T3 (OSRAM) |
| ES (1) | ES2900105T3 (OSRAM) |
| HR (1) | HRP20211698T1 (OSRAM) |
| HU (1) | HUE056885T2 (OSRAM) |
| IL (3) | IL279734B2 (OSRAM) |
| LT (1) | LT3587418T (OSRAM) |
| MA (1) | MA50675B1 (OSRAM) |
| MX (2) | MX2023013508A (OSRAM) |
| PL (1) | PL3587418T3 (OSRAM) |
| PT (1) | PT3587418T (OSRAM) |
| RS (1) | RS62732B1 (OSRAM) |
| SA (1) | SA520420909B1 (OSRAM) |
| SG (1) | SG11202012767UA (OSRAM) |
| SI (1) | SI3587418T1 (OSRAM) |
| SM (1) | SMT202100636T1 (OSRAM) |
| WO (1) | WO2020006483A1 (OSRAM) |
| ZA (1) | ZA202100509B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019295790B2 (en) * | 2018-06-29 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting creb binding protein (CBP) |
| WO2020190791A1 (en) | 2019-03-15 | 2020-09-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (creb) |
| WO2020190792A1 (en) * | 2019-03-15 | 2020-09-24 | Forma Therapeutics, Inc. | Compositions and methods for treating androgen receptor positive forms of cancer |
| JP2023532675A (ja) | 2020-06-25 | 2023-07-31 | トルレモ・セラピューティクス・アクチェンゲゼルシャフト | ＥＧＦＲ突然変異ＮＳＣＬＣの治療に使用するための、ＣＢＰ／ｐ３００ブロモドメイン阻害剤およびＥＧＦＲ阻害剤の組合せ |
| US12472179B2 (en) | 2020-06-25 | 2025-11-18 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4404207A (en) | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
| US5138089A (en) * | 1986-06-27 | 1992-08-11 | The Procter & Gamble Company | Chromophores, sunscreen compositions and methods for preventing sunburn |
| WO1995020589A1 (en) | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| DE60134886D1 (de) | 2000-11-20 | 2008-08-28 | Merck Patent Gmbh | Chirale photoisomerisierbare verbindungen |
| CA2463136A1 (en) | 2001-10-17 | 2003-04-24 | Raymond Andersen | Ship 1 modulators |
| EP1460067A4 (en) | 2001-11-26 | 2005-12-07 | Takeda Pharmaceutical | BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| TWI322012B (en) | 2002-12-20 | 2010-03-21 | Organon Nv | Tetrahydroquinoline derivatives |
| IN2003CH00929A (OSRAM) | 2003-11-13 | 2008-10-06 | ||
| US20080188527A1 (en) | 2003-12-23 | 2008-08-07 | Cashman John R | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer |
| JP4790703B2 (ja) | 2004-04-07 | 2011-10-12 | 武田薬品工業株式会社 | 環式化合物 |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| WO2007120339A1 (en) | 2005-12-19 | 2007-10-25 | Genentech, Inc. | Pyrimidine kinase inhibitors |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| BRPI0713096A2 (pt) | 2006-05-09 | 2012-10-16 | Hemaquest Pharmaceuticals Inc | métodos para tratar distúrbios sangüìneos |
| EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| CA2574531C (en) | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| IN2014MN02330A (OSRAM) | 2007-06-21 | 2015-08-14 | Wistar Inst | |
| JP5492770B2 (ja) | 2007-06-26 | 2014-05-14 | サノフイ | ベンゾイミダゾール及びアザベンゾイミダゾールの位置選択的銅触媒合成 |
| EP2172453A4 (en) | 2007-06-27 | 2010-12-22 | Taisho Pharmaceutical Co Ltd | CONNECTION WITH 11-β-HSD1 INHIBITING ACTIVITY |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| HUE060249T2 (hu) | 2008-06-16 | 2023-02-28 | Univ Tennessee Res Found | Vegyületek rák kezelésére |
| EP2412710A4 (en) * | 2009-03-27 | 2012-08-08 | Kowa Co | Fused piperidine compound and pharmaceutical agent comprising same |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| CA2758904C (en) | 2009-04-15 | 2017-04-04 | Jw Pharmaceutical Corporation | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| WO2010138490A1 (en) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of mtor and methods of their use and manufacture |
| US8637499B2 (en) | 2009-05-26 | 2014-01-28 | Exelixis, Inc. | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture |
| WO2011085039A2 (en) | 2010-01-05 | 2011-07-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| AU2010347233B2 (en) | 2010-03-01 | 2015-06-18 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| WO2011150156A2 (en) | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| WO2012019093A1 (en) | 2010-08-05 | 2012-02-09 | Human Biomolecular Research Institute | Synthetic compounds and methods to decrease nicotine self-administration |
| WO2012080729A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| US9295754B2 (en) | 2011-02-24 | 2016-03-29 | Emory University | Noggin inhibitory compositions for ossification and methods related thereto |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| WO2013148114A1 (en) | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| US9211333B2 (en) | 2012-06-05 | 2015-12-15 | Hong Kong Baptist University | Anti-cancer agents synthesized based on miliusane compounds |
| JP2015529242A (ja) | 2012-09-21 | 2015-10-05 | アドヴィヌス セラピューティクス リミテッドＡｄｖｉｎｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 置換された縮合三環式化合物、組成物およびその医薬用途 |
| RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| ES2661437T3 (es) | 2013-06-21 | 2018-04-02 | Zenith Epigenetics Corp. | Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| KR20160034379A (ko) | 2013-07-25 | 2016-03-29 | 다나-파버 캔서 인스티튜트 인크. | 전사 인자의 억제제 및 그의 용도 |
| DE102013215912B3 (de) | 2013-08-12 | 2015-02-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung |
| AR098414A1 (es) | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
| DK3071203T3 (da) | 2013-11-18 | 2021-03-15 | Forma Therapeutics Inc | Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| WO2016044694A1 (en) | 2014-09-19 | 2016-03-24 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
| WO2016086200A1 (en) * | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| EP3242878B1 (en) | 2015-01-08 | 2020-10-14 | Impetis Biosciences Ltd. | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| US11883381B2 (en) | 2016-05-12 | 2024-01-30 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| CN115028617A (zh) | 2016-05-24 | 2022-09-09 | 基因泰克公司 | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617627D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| US10617680B2 (en) * | 2017-04-18 | 2020-04-14 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| WO2019055877A1 (en) * | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| AU2019295790B2 (en) * | 2018-06-29 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting creb binding protein (CBP) |
-
2019
- 2019-06-28 AU AU2019295790A patent/AU2019295790B2/en active Active
- 2019-06-28 MX MX2023013508A patent/MX2023013508A/es unknown
- 2019-06-28 MX MX2020014303A patent/MX2020014303A/es unknown
- 2019-06-28 SG SG11202012767UA patent/SG11202012767UA/en unknown
- 2019-06-28 KR KR1020257014745A patent/KR20250067962A/ko active Pending
- 2019-06-28 BR BR112020026783-0A patent/BR112020026783A2/pt unknown
- 2019-06-28 IL IL279734A patent/IL279734B2/en unknown
- 2019-06-28 CN CN202211658329.8A patent/CN116178369A/zh active Pending
- 2019-06-28 WO PCT/US2019/039936 patent/WO2020006483A1/en not_active Ceased
- 2019-06-28 CA CA3105099A patent/CA3105099A1/en active Pending
- 2019-06-28 KR KR1020217002866A patent/KR102805503B1/ko active Active
- 2019-06-28 US US16/457,596 patent/US10870648B2/en active Active
- 2019-06-28 CN CN201980050022.XA patent/CN112513038B/zh active Active
- 2019-06-28 IL IL321337A patent/IL321337A/en unknown
- 2019-07-01 SM SM20210636T patent/SMT202100636T1/it unknown
- 2019-07-01 JP JP2019123100A patent/JP6781806B2/ja active Active
- 2019-07-01 SI SI201930136T patent/SI3587418T1/sl unknown
- 2019-07-01 PL PL19183741T patent/PL3587418T3/pl unknown
- 2019-07-01 HU HUE19183741A patent/HUE056885T2/hu unknown
- 2019-07-01 PT PT191837418T patent/PT3587418T/pt unknown
- 2019-07-01 HR HRP20211698TT patent/HRP20211698T1/hr unknown
- 2019-07-01 DK DK19183741.8T patent/DK3587418T3/da active
- 2019-07-01 EP EP21193994.7A patent/EP3998266A1/en active Pending
- 2019-07-01 ES ES19183741T patent/ES2900105T3/es active Active
- 2019-07-01 RS RS20211321A patent/RS62732B1/sr unknown
- 2019-07-01 LT LTEP19183741.8T patent/LT3587418T/lt unknown
- 2019-07-01 MA MA50675A patent/MA50675B1/fr unknown
-
2020
- 2020-05-28 JP JP2020093126A patent/JP7017801B2/ja active Active
- 2020-06-08 US US16/946,159 patent/US11254674B2/en active Active
- 2020-12-17 JP JP2020209005A patent/JP2021042255A/ja not_active Withdrawn
- 2020-12-28 SA SA520420909A patent/SA520420909B1/ar unknown
-
2021
- 2021-01-25 ZA ZA2021/00509A patent/ZA202100509B/en unknown
- 2021-11-22 CY CY20211101010T patent/CY1124762T1/el unknown
-
2022
- 2022-02-10 US US17/669,112 patent/US12378242B2/en active Active
-
2023
- 2023-09-05 AU AU2023226653A patent/AU2023226653B2/en active Active
-
2024
- 2024-06-09 IL IL313466A patent/IL313466B2/en unknown
-
2025
- 2025-03-21 JP JP2025046918A patent/JP2025094157A/ja active Pending
- 2025-07-29 AU AU2025210762A patent/AU2025210762A1/en active Pending